Skip to content
AnalystLens

Medpace Holdings Annual Report, Year Ended Dec 31, 2024

Filing Date
Filed February 11, 2025
Period End
December 31, 2024
Security
MEDP
In the record · 2016–202610-K1010-Q318-K90

MEDP filed 10 annual reports (10-K), 31 quarterly reports (10-Q) and 90 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Dec ’17Dec ’17
  2. Leadership change8-K · Mar ’20Mar ’20
  3. Material agreement8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Jun ’26Jun ’26

Summary

Summary of the 10-K filed February 11, 2025. Cited figures are marked; the original filing is the authoritative source.

Medpace Holdings, Inc. (NASDAQ: MEDP) describes itself as one of the world's leading clinical contract research organizations by revenue, focused solely on outsourced Phase I-IV clinical development services for biotechnology, pharmaceutical and medical device companies.

For the year ended December 31, 2024, net revenue was $2,109.1 milliona, up $223.2 million (11.8%) from $1,885.8 million in 2023. Income from operations rose to $446.9 million from $336.8 million, and net income increased to $404.4 million from $282.8 million, with diluted EPS of $12.63 compared with $8.88. Growth was described as broad based but primarily driven by Metabolic, Oncology, Cardiology and other uncategorized therapeutic areas.

Net new business awards were $2,230.0 millionb in 2024 versus $2,356.7 million in 2023. Backlog rose $89.2 million, or 3.2%, to $2,902.2 million at December 31, 2024, of which approximately $1,620.0 million to $1,640.0 million is expected to convert to net revenue in 2025. Cash and cash equivalents increased to $669.4 million from $245.4 million, operating cash flow was $608.8 million, and the company had no indebtedness at year end.

The company repurchased $174.2 millionc of stock in the fourth quarter alone for the year-ended 2024 program, and in February 2025 the Board added $600.0 million to its repurchase program. The filing highlights concentration and structural risks: the top ten customers generated approximately 28.9% of net revenue, most contracts are terminable on about 30 days' notice, and the CEO and founder, August J.

Troendle, controls approximately 17.6%d of outstanding shares. Deloitte & Touche LLP audited the financial statements and reported effective internal control over financial reporting as of December 31, 2024.

Key Highlights

  1. Net revenue rose 11.8% to $2,109.1 million in 2024, from $1,885.8 million in 2023.
  2. Net income increased to $404.4 million from $282.8 million; diluted EPS was $12.63 versus $8.88.
  3. Backlog increased 3.2% to $2,902.2 million at December 31, 2024; about $1,620.0 million to $1,640.0 million is expected to convert to 2025 revenue.
  4. Net new business awards declined to $2,230.0 million from $2,356.7 million in 2023.
  5. Cash and cash equivalents rose to $669.4 million, with operating cash flow of $608.8 million and no indebtedness as of December 31, 2024.
  6. The Board approved an increase of $600.0 million to the stock repurchase program as of February 6, 2025, after $134.6 million remained under the prior authorization.
  7. Top ten customers accounted for approximately 28.9% of net revenue, and no single customer exceeded 10%; the CEO and founder controls approximately 17.6% of outstanding shares.

Financial Statements

FY2024 against FY2023

Line itemFY2024FY2023Change
Revenue$2.11B$1.89B+11.8%
SG&A Expenses$180.18M$161.35M+11.7%
Operating Expenses$1.66B$1.55B+7.3%
Operating Income$446.87M$336.82M+32.7%
Net Income$404.39M$282.81M+43.0%
EPS (Basic)$13.06$9.20+42.0%
EPS (Diluted)$12.63$8.88+42.2%
Shares Outstanding (Basic)30.96M30.72M+0.8%
Shares Outstanding (Diluted)32.01M31.84M+0.5%

Frequently Asked Questions

  1. How profitable was Medpace in 2024 compared with 2023?

    Income from operations was $446.9 million in 2024 versus $336.8 million in 2023, and net income was $404.4 million versus $282.8 million. Income tax provision was $71.5 million, with an effective tax rate of 15.0% compared with 15.8% in 2023.

  2. What does the backlog indicate about future revenue?

    Backlog was $2,902.2 million at December 31, 2024, and the company expects approximately $1,620.0 million to $1,640.0 million of it to convert to net revenue in 2025. The filing cautions that backlog is not necessarily a meaningful predictor of future results because most contracts are terminable without cause.

  3. What are the main customer concentration risks?

    Small biopharmaceutical companies generated 79% of 2024 net revenue and mid-sized companies generated 17%. The top ten customers accounted for approximately 28.9% of net revenue, and most customers can terminate contracts on 30 days' notice.

  4. How is Medpace returning capital to shareholders?

    The company repurchased $169.9 million of common stock in financing cash flows in 2024 and $174.2 million under the new program for the year. It had $134.6 million remaining under that program at December 31, 2024, and the Board added $600.0 million in February 2025. The company has not paid dividends and has no current plans to do so.

  5. Who controls the company and what governance risk does that create?

    CEO and founder August J. Troendle directly owns 654,656 shares and beneficially owns 4,733,019 shares held by Medpace Investors LLC, or approximately 17.6% of outstanding common stock. The filing states he can exert significant influence over director elections, bylaw amendments and major transactions, including a sale of substantially all assets.